Nonprofit research organization Cure Alzheimer's Fund has expanded its Board of Directors by adding three prominent professionals with significant business and personal connections to Alzheimer's disease. Mary Greenhill Cagliero, Mark Faggiano, and Kumar Mahadeva were selected to bring new perspectives and leadership to the organization's mission of preventing, slowing, and potentially reversing Alzheimer's disease.
The appointments reflect the organization's commitment to strategic growth and innovative approaches to combating a disease that affects millions of families worldwide. Each new board member brings a compelling personal narrative and professional expertise that could significantly impact the organization's research and fundraising efforts.
Mary Greenhill Cagliero, with a background in investment banking and entrepreneurship, joins the board with a deeply personal connection to Alzheimer's. Her mother, Gayle, passed away from the disease in 2017, motivating her involvement. Cagliero's professional experience at Goldman Sachs and as a business founder could provide valuable strategic insights for the organization.
Mark Faggiano, a successful technology entrepreneur known for founding TaxJar and leading it to acquisition by Stripe, brings entrepreneurial leadership to the board. His father's death from Alzheimer's in 2021 provides a personal motivation for his involvement. Faggiano's experience in scaling innovative businesses could help Cure Alzheimer's Fund enhance its research funding and operational strategies.
Kumar Mahadeva, founder of Cognizant Technology Solutions, adds extensive corporate and technology leadership to the board. Having lost his own father to Alzheimer's in 2013, Mahadeva's involvement represents a continued commitment to advancing medical research. His experience on various boards and international advisory committees could help the organization expand its global research network.
Since its founding in 2004, Cure Alzheimer's Fund has provided 927 grants to over 300 researchers and contributed more than $223 million to Alzheimer's research. The organization has achieved a perfect score from Charity Navigator for 13 consecutive years, demonstrating its commitment to transparency and effective resource allocation.
The addition of these board members signals a strategic approach to addressing one of the most challenging neurological conditions of our time. By combining personal passion with professional expertise, Cure Alzheimer's Fund aims to accelerate research that could potentially transform understanding and treatment of Alzheimer's disease.
